Latest From DCPrime BV
Interim Phase II data has shown that SOTIO's dendritic cell-based cancer vaccine candidates have efficacy in patients with ovarian cancer and non-small cell lung cancer.
The exercising by Janssen Biotech of an option to develop OSE Immunotherapeutics’ Phase II-ready antibody fragment for autoimmune and transplant-associated disorders will give an early boost to the French biotech that only completed a merger several weeks ago.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced September through October 2013.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- DCPrime BV
- Senior Management
- Marcel Zwaal, CEO
- Contact Info
Phone: 071 332 2626q
BioPartner Leiden, 2333
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.